Trial Profile
A multicenter, open-label trial to evaluate the effects of zoledronic acid on circulating tumor cells in patients with castration resistant prostate cancer (CRPC) with bone metastasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2014
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms CRPC with BM/ZOL-CTC
- 26 May 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 15 Jan 2014 Planned End Date changed from 1 Dec 2013 to 31 Mar 2014, as reported by University Hospital Medical Information Network - Japan.
- 15 Jan 2014 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan.